ArticleMedicine2025
Coronavirus disease 2019 and catastrophic antiphospholipid syndrome: Case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe emergence of catastrophic antiphospholipid syndrome (CAPS) alongside coronavirus disease 2019 (COVID-19) is of great concern, because of its high mortality and unclear mechanism. This severe disease, characterized by multiple thrombi and multisystem disorder, has notably diverse clinical presentations, which complicates its diagnosis in clinical practice. Now, we report a rare case of CAPS in a patient with COVID-19. PATIENT CONCERNS: A 64-year-old patient who mainly presented with pain and swelling 2 months ago progressed gradually into multiple thrombi, including pulmonary embolism, renal embolism, and deep vein thrombosis; transient ischemic attack; multiple organ dysfunction with acute kidney injury; and necrosis of both lower limbs, left upper extremity, both ears, and penile gangrene. DIAGNOSES: He was diagnosed as CAPS with COVID-19 by positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) testing and high-titer immunoglobulin (Ig) A anti-β2-glycoprotein I antibody (anti-β2GPI).
interventionsActive rescue treatments such as anticoagulants, plasmapheresis, glucocorticoid pulse therapy, antibiotics, and multi-organ functional support alleviated the disease effectively. OUTCOMES: Although his clinical symptoms were successfully controlled, we could not save the necrotic tissue. The patient refused to undergo limb amputation and died of necrotic tissue infection. LESSONS: CAPS in patients with COVID-19 is an extremely serious disease with a high mortality rate. A delay in diagnosis and treatment can result in potentially devastating consequences. Therefore, physicians should be alert to the possibility of CAPS in patients with multiple thrombi and COVID-19. Furthermore, this case serves as a foundation upon which future studies can build to investigate the possible mechanisms of IgA anti-β2GPI-positive CAPS in patients with COVID-19, which may guide the exploration of potential therapeutic strategies to prevent the disease's progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.